Evidence map›Paper›PMID 40875918›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Engineered Probiotic-Powered Micro-Rod Robot Bomb for Thrombus-Penetrating Explosion.

Riyue Liu, Jiale Chen, Yuanyuan Li, Nawsherwan, Cuilian Dai, Yan Wang, Jinrong Zheng, Kecheng Zhou, Mangmang Sang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Engineered Probiotic-Powered Micro-Rod Robot Bomb for Thrombus-Penetrating Explosion.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Riyue LiuXiamen Cardiovascular Hospital of Xiamen University, School of Medicine, Fujian Branch of National Clinical Research Center for Cardiovascular Diseases, Xiamen, 361006, China.
Jiale ChenXiamen Cardiovascular Hospital of Xiamen University, School of Medicine, Fujian Branch of National Clinical Research Center for Cardiovascular Diseases, Xiamen, 361006, China.
Yuanyuan LiXiamen Cardiovascular Hospital of Xiamen University, School of Medicine, Fujian Branch of National Clinical Research Center for Cardiovascular Diseases, Xiamen, 361006, China.
NawsherwanXiamen Cardiovascular Hospital of Xiamen University, School of Medicine, Fujian Branch of National Clinical Research Center for Cardiovascular Diseases, Xiamen, 361006, China.
Cuilian DaiXiamen Cardiovascular Hospital of Xiamen University, School of Medicine, Fujian Branch of National Clinical Research Center for Cardiovascular Diseases, Xiamen, 361006, China.
Yan WangXiamen Cardiovascular Hospital of Xiamen University, School of Medicine, Fujian Branch of National Clinical Research Center for Cardiovascular Diseases, Xiamen, 361006, China.
Jinrong ZhengXiamen Cardiovascular Hospital of Xiamen University, School of Medicine, Fujian Branch of National Clinical Research Center for Cardiovascular Diseases, Xiamen, 361006, China.
Kecheng ZhouThe Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, School of Rehabilitation Medicine, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China.
Mangmang SangXiamen Cardiovascular Hospital of Xiamen University, School of Medicine, Fujian Branch of National Clinical Research Center for Cardiovascular Diseases, Xiamen, 361006, China.ORCID https://orcid.org/0000-0002-2157-0892

Funding

Fujian Provincial Health Commission Science and technology program 2023GG01010026Fujian Provincial Natural Science Foundation of China 2023J011681Fujian Provincial Natural Science Foundation of China 2023J011683National Natural Science Foundation of China 32100105Xiamen Health and Technology High-quality Development Project 2024GZL-GG03
6 · The paper itself

Abstract

Conventional thrombolytic agents demonstrated limited efficacy in treating thrombotic disorders characterized by narrow therapeutic windows and progressive vascular injury, lacking the required precision, timeliness, and treatment durability. Here an engineered probiotic powered micro-rod robot for targeted and penetrative treatment for thrombus is developed. This micro-rod robot (

Indexed as

Drug Delivery SystemsProbioticsRoboticsThrombolytic TherapyThrombosisAnimalsFibrinolytic AgentsHumansMiceFibrinolytic Agentsmicro‐rodpenetratingprobioticrobotsecondary thrombosis

Identifiers

PMID40875918
PMCPMC12463029

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.